Global Acute Bacterial Skin And Skin Structure Infections Market Anticipated To Grow To $20.79 Billion By 2030 At 10.2% CAGR
The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.
What Is The Expected Market Size Of The Acute Bacterial Skin And Skin Structure Infections Market In 2026 And How Much Will It Reach By 2030?
The market for acute bacterial skin and skin structure infections has experienced significant growth in recent years. This market is expected to expand from $12.9 billion in 2025 to $14.09 billion in 2026, achieving a compound annual growth rate (CAGR) of 9.2%. Historically, this expansion can be attributed to factors such as the limited availability of broad-spectrum antibiotics, an increasing prevalence of hospital-acquired infections, heightened awareness regarding skin infection complications, improved access to community healthcare, and the adoption of standard infection control protocols.
The acute bacterial skin and skin structure infections market size is projected to experience swift expansion over the coming years. This market is set to reach $20.79 billion by 2030, driven by a compound annual growth rate (CAGR) of 10.2%. This anticipated growth during the forecast period stems from factors such as the advancement of next-generation antibiotics, increased financial commitments to antimicrobial research, the proliferation of community-based infection management initiatives, the broadening of hospital pharmacy distribution networks, and the deployment of quick diagnostic technologies. Key developments expected within this period involve a rising frequency of acute bacterial skin and skin structure infections, the increasing uptake of innovative antibiotics and combination treatments, the enlargement of hospital and community healthcare infrastructures, a greater reliance on oral and parenteral antibiotics, and a concentrated effort to decrease hospital-acquired infection rates.
Download A Free Sample Report For Comprehensive Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=13282&type=smp
Which Major Factors Are Contributing To The Development Of The Acute Bacterial Skin And Skin Structure Infections Market?
The increasing occurrence of skin infections is anticipated to boost the growth of the acute bacterial skin and skin structure infections market moving forward. Skin infections are conditions where microorganisms, such as bacteria, fungi, or viruses, invade and multiply within the skin, causing various symptoms and discomfort. This uptick in skin infections generates a higher demand for therapeutic solutions, antibiotics, and innovative treatments designed to address acute bacterial and skin structure infections, thus ensuring patients receive the best possible care and outcomes. For example, in March 2023, the World Health Organization, a Switzerland-based specialized agency of the United Nations, reported that around 1.8 billion people globally suffer from skin conditions at any given time. Among these, Neglected Tropical Diseases (NTDs) constitute approximately 10%, fungal infections 34%, and bacterial infections 23%, often resulting in high mortality rates. Hence, the rising prevalence of skin infections will drive the expansion of the acute bacterial skin and skin structure infections market.
What Key Segment Areas Are Included In The Acute Bacterial Skin And Skin Structure Infections Market Assessment?
The acute bacterial skin and skin structure infections market covered in this report is segmented –
1) By Type Of Infection: Hospital-Acquired Acute Bacterial Skin And Skin Structure Infections, Community-Acquired Acute Bacterial Skin And Skin Structure Infections
2) By Active Ingredients: Delafloxacin, Vancomycin, Ceftaroline Fosamil, Oritavancin, Tedizolid, Daptomycin, Tigecycline, Linezolid, Other Active Ingredients
3) By Route Of Administration: Oral, Parenteral
4) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies
Subsegments:
1) By Hospital-Acquired Acute Bacterial Skin And Skin Structure Infections (HABSSSIs): Surgical Site Infections, Catheter-Related Infections, Infections Related To Medical Devices
2) By Community-Acquired Acute Bacterial Skin And Skin Structure Infections (CABSSSIs): Cellulitis, Abscesses, Impetigo, Folliculitis, Wound Infections
Which Trends Are Guiding The Development Of The Acute Bacterial Skin And Skin Structure Infections Market?
Key players operating within the acute bacterial skin and skin structure infections market are focusing on the creation of advanced single-dose therapies, like Dalbonova, to gain a competitive advantage. Dalbonova is a single-dose treatment designed for convenience and effectiveness, enabling patients to achieve their intended results through a single powerful 1500 mg administration. For instance, in August 2023, BDR Pharmaceuticals International Pvt. Ltd., an India-based pharmaceutical company with a focus on active pharmaceutical ingredient (API) and formulation segments, including acute bacterial skin and skin structure infections, launched Dalbonova injection, a single-dose therapy for acute bacterial skin and skin structure infections (ABSSSI). Dalbonova Injection minimizes the risk of hospital-acquired conditions by offering a one-time treatment and removing the need for hospitalizations. It is developed to address acute bacterial skin and skin structure infections (ABSSSI) caused by certain gram-positive microorganisms in individuals of all ages, including newborns.
Who Are The Major Companies Operating In The Acute Bacterial Skin And Skin Structure Infections Market?
Major companies operating in the acute bacterial skin and skin structure infections market are Pfizer Inc., AbbVie Inc., Novartis AG, GSK PLC, Takeda Pharmaceutical Company Limited, Viatris Inc., Teva Pharmaceutical Industries Ltd., Sun Pharmaceutical Industries Limited, Dr. Reddy’s Laboratories Ltd., Cipla Limited, Lupin Limited, Zydus Lifesciences Limited, Aurobindo Pharma Limited, Glenmark Pharmaceuticals Ltd., Alkem Laboratories Limited, Aspen Pharmacare Holdings Limited, Melinta Therapeutics LLC, Abbott Laboratories, Fresenius SE & Co. KGaA, Menarini Group
Access The Complete Acute Bacterial Skin And Skin Structure Infections Market Report:
Which Regional Market Leads The Acute Bacterial Skin And Skin Structure Infections Market?
Asia-Pacific was the largest region in the acute bacterial skin and skin structure infections market in 2025. North America is expected to be the fastest-growing region in the forecast period. The regions covered in the acute bacterial skin and skin structure infections market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Access Acute Bacterial Skin And Skin Structure Infections Market Report for Deeper Competitive Insights
https://www.thebusinessresearchcompany.com/customise?id=13282&type=smp
Browse Through More Reports Similar to the Global Acute Bacterial Skin And Skin Structure Infections Market 2026, By The Business Research Company
Complicated Skin And Skin Structure Infections Drugs Global Market Report 2026
Antimicrobial Medical Device Coatings Global Market Report 2026
Dermatitis Drugs Global Market Report 2026
https://www.thebusinessresearchcompany.com/report/dermatitis-drugs-global-market-report
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
